Investor directory

CBC Group

CBC Group is a private equity and venture capital firm established in 2014, specializing in the healthcare sector. The firm focuses on investments across various stages, including incubation, growth capital, and buyouts, with a particular emphasis on life sciences, medical technology, biotechnology, pharmaceuticals, and medical services. CBC Group targets specific areas such as the treatment of Hepatitis B and lung cancer, aiming for controlling acquisition opportunities in pharmaceutical and biotechnology sectors. Based in Singapore, with additional offices in the Asia-Pacific region, the United States, and Israel, the firm leverages its extensive network and expertise to facilitate cross-border investments and strategic alliances, ultimately striving to maximize returns for its global clients.

Focus

Scale StageChinaPharmaceuticalsAsiaSeries BShow more
http://www.c-bcap.com
http://www.cbridgecap.com
https://crunchbase.com/organization/c-bridge-capital
https://crunchbase.com/organization/cbridge-capital
https://linkedin.com/company/c-bridge-capital
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=266150747
https://www.privateequityinternational.com/database/#/profile?id=18605

James Cen Bonsor

Director

Lisa Chaves

Managing Director

Wei Fu

CEO

Henry Yan

Vice President

34 past transactions

I-Mab HK

Series C in 2018
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

CMAB BioPharm

Private Placement in 2018
CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

Adcentrx Therapeutics

Series A in 2021
Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Yaneng Bioscience

Venture Round in 2022
Yaneng Biotechnology produces a gene diagnostic chip technology platform. They provide cervical cancer screening and hereditary disease diagnostics, such as pre pregnancy and prenatal diagnosis and screening tests, and automatic nucleic acid extractor. They also provide resarch and development services.

Yourui Pharmaceutical Technology

Private Placement in 2018
Yourui Pharmaceutical Technology operates as a pharmaceutical company. The company is based in Shanghai, China.

Hangzhou Chain Medical Labs Co., Ltd.

Private Placement in 2018
Hangzhou Chain Medical Labs Co., Ltd. operates as a medical laboratory. It offers clinical laboratory, clinical trial, research, and laboratory information system services to support various medical institutions, as well as assist in obtaining ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process, and external audit services. The company is based in Hangzhou, China.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

GrayBug

Private Placement in 2019
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

Clarus Therapeutics

Venture Round in 2014
Clarus Therapeutics, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. Clarus Therapeutics, Inc. was founded in 2003 and is based in Northbrook, Illinois.

I-Mab HK

Series C in 2018
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

Hangzhou Chain Medical Labs Co., Ltd.

Private Placement in 2018
Hangzhou Chain Medical Labs Co., Ltd. operates as a medical laboratory. It offers clinical laboratory, clinical trial, research, and laboratory information system services to support various medical institutions, as well as assist in obtaining ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process, and external audit services. The company is based in Hangzhou, China.

Nuance Biotech

Private Placement in 2018
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

GrayBug

Series C in 2019
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

Anrei Medical

Venture Round in 2017
Anrei medical (hz)co.,ltd, a US wholly owned and FDA registered enterprise, was founded 2006. The company has been developing disposable medical devices for use in a variety of minimally invasive procedures since inception and is a high-tech company vertically integrated in the areas of research and development, manufacturing, distribution and customer service.

CMab Biopharm Inc.

Private Placement in 2018
CMab Biopharm Inc. operates as a contract development and manufacturing organization (CDMO) providing pharmaceutical services to biopharma companies. It provides good manufacturing practice (GMP) services, including cell line development, GMP production, and regulatory support for biopharmaceutical research and development companies. The company is based in Suzhou, China.

I-Mab HK

Private Placement in 2018
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

FitSAMO

Series A in 2016
FitSAMO is an orthopaedic surgical equipment supplier.

Nuance Biotech

Series D in 2020
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

YS Biopharma

Venture Round in 2022
Yisheng Biopharma Co., Ltd., a biopharmaceutical company, researches, develops, manufactures, and markets immuno-oncology products and vaccines. It offers YS-ON-001, an investigational biological product that demonstrates immuno-modulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells for the treatment of advanced solid tumors. Yisheng Biopharma Co., Ltd. was founded in 2002 and is based in Beijing with operations in China, the United States, Cambodia, and Singapore.

Nuance Biotech

Series B in 2018
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

NiKang Therapeutics

Private Placement in 2020
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

CMAB BioPharm

Series B in 2018
CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

I-Mab HK

Series B in 2017
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

Ascletis

Series B in 2017
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.

CMAB BioPharm

Series A in 2018
CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

Nuance Biotech

Private Placement in 2020
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

Everest Medicines

Private Placement in 2020
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.

FitSAMO

Angel Round in 2015
FitSAMO is an orthopaedic surgical equipment supplier.

I-Mab HK

Series A in 2016
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

Ascletis

Series B in 2015
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.

Adcentrx Therapeutics

Series A in 2021
Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.